Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


September 26-28, 2017
Hynes Convention Center,
Boston, MA

The most complete event to successfully blueprint cell, gene, and immunotherapies from proof of concept to commercialization

Thank you to all of those who attended Cell & Gene Therapy Bioprocessing & Commercialization 2016! Mark your calendar to join us at next year's meeting, held September 26-28, 2017 at the Hynes Convention Center in Boston. Sign up for our email updates below for program updates and registration offers.

Fox25 News Coverage of Biotech Week Boston

Biotech Week Boston Partnering App

All attendees of Biotech Week Boston have access to the partnering app, which allows you to view the attendee list, send messages, view onsite event photos and access speaker presentations.

If you attended Biotech Week Boston and need your log in details, please email and our team will get back to you within 48 hours.

Accelerate Your Cell and Gene-Based products towards commercial success

Navigate the Pathway to Commercialization

Gain insights from 80+ global thought-leading speakers on how overcome today’s challenges involving scale-up, facility design, characterization, tech transfer, regulatory approval, investment, reimbursement and more. New in-depth content added includes:

  • Gene Therapy
  • Immuno-Oncology
  • Regulatory Concerns
Ensure a Successful Product-to-Market Launch

Evaluate leading technologies by meeting face-to-face with 25+ international CMOs, CROs and who can accelerate your product towards commercial success.

Meet the Right Partners to Grow Your Business

Connect with 300+ thought-leaders and service providers who can offer the strategic, technical and financial support to ensure a success cell-based product launch.

What Makes This Event Unique

Six Focused Tracks

Keep your team up to date on the latest science, technologies and industry updates across the entire spectrum of cell therapy, gene therapy, and immuno-oncology product development:

  • NEW! Regulatory Considerations
  • NEW! Immuno-Oncology
  • NEW! Gene Therapy Development & Production
  • Cell Therapy Bioprocessing
  • Tools & Technologies
  • Commercialization
Content For All Company Types

This year’s event presents a complete blueprint from bench to commercial scale that’s accessible for any sized company, including:

  • Mid-Sized Gene and Cell Therapy Companies
  • Biotech Start-Ups 
  • Virtual Companies
  • Large Pharma and Biotechs
  • Academic Institutions
Why People Come Back

"The go-to conference for everything related to Cell Therapy Bioprocessing and Commercialization.Great technology, a comprehensive program, and a wonderful exhibit hall. This conference is a great place to do business.” — Jon Rowley, Rooster Bio

“The only one of its kind.” — Mahendra Rao, NYSCF

“This is a great event to keep abreast of the manufacturing advancements for the rapidly evolving cell and gene therapy industry.” — Brian Hampson, PCT, A Caladrius Company

Progress Toward Commercial Scale and Efficiency in Cell Therapy Bioprocessing

Cell and gene therapy is an extremely promising and growing medical technology sector with 631 ongoing clinical trials at the end of 2015. It is applicable to oncology, cardiovascular disease, infectious diseases and other diseases. The merit of cell and gene therapy has been demonstrated by FDA approvals, however commercialisation can prove a high hurdle that can trip up even approved therapeutics such as Dendreon’s Provenge autologous cell therapy. There are however steps that can be taken to reduce the risk associated with commercialisation that companies with a cell and gene therapy portfolio should consider. This whitepaper discusses practical measures to improve the chances of commercial success:

  • Characterization and Comparability Risk reduction through Quality by Design (QbD)
  • Improving efficiency and reducing costs in development and production
  • Novel analytical technologies and methodologies
  • Ensuring successful process scale up and transfer
  • Progress towards the industrialization of cell and gene therapies through modularisation

Networking Reception Co-Sponsor